CSIMarket Company Name, Ticker, Competitors, else..
 

Deciphera Pharmaceuticals Inc   (NASDAQ: DCPH)

Deciphera Pharmaceuticals Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

DCPH Sales vs. its Competitors Q1 2024


Comparing the current results to its competitors, Deciphera Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2024 by 34.55 % year on year, while most of its competitors have experienced contraction in revenues by -8.39 %, achieved in the same quarter.

• List of DCPH Competitors





Revenue Growth Comparisons




Net Income Comparison

Deciphera Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -33.36 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -33.36 %

<<  DCPH Stock Performance Comparisons





  

Overall company Market Share Q1 2024
Due to strong revenue growth of 34.55 % in Overall company Deciphera Pharmaceuticals Inc improved its market share, to approximately 0.19 %.


<<  More on DCPH Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Deciphera Pharmaceuticals Inc




Effector Therapeutics Inc
Share Performance



+300.00%
Over The Past 5 Days
Effector Therapeutics Inc
Profile

Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.

More about Effector Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.003 mill. $ - mill. $ -34.631 mill.


Affimed N v
Share Performance



0.00%
30 Days
Affimed N v
Profile

Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.

More about Affimed N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 10.781 mill. $ -150.656 mill.


Adc Therapeutics Sa
Share Performance



+20.00%
30 Days
Adc Therapeutics Sa
Profile

Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.

More about Adc Therapeutics Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 204.621 mill. $ 79.584 mill. $ -96.908 mill.


Adagene Inc
Share Performance



+69.27%
One Year
Adagene Inc
Profile

Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.

More about Adagene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 217.733 mill. $ 7.671 mill. $ -17.609 mill.


Aclaris Therapeutics Inc
Share Performance



+3.34%
30 Days
Aclaris Therapeutics Inc
Profile

Aclaris Therapeutics Inc is a company that focuses on developing and commercializing innovative therapies to address significant unmet needs in dermatology and immunology. Their business model involves researching and developing treatments for various skin and hair conditions, obtaining regulatory approvals, and marketing these therapies to healthcare professionals and patients.

More about Aclaris Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 796.046 mill. $ 8.367 mill. $ -69.662 mill.

168 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Deciphera Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Deciphera Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.